These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. B cells as therapeutic targets for rheumatic diseases. Looney RJ; Anolik J; Sanz I Curr Opin Rheumatol; 2004 May; 16(3):180-5. PubMed ID: 15103242 [TBL] [Abstract][Full Text] [Related]
14. Biologic agents in the treatment of inflammatory rheumatic diseases. Kalden JR; Manger B Curr Opin Rheumatol; 1995 May; 7(3):191-7. PubMed ID: 7612410 [TBL] [Abstract][Full Text] [Related]
15. [Progression and direction of humanized antibody research]. Lin Y; Yan XY Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479 [TBL] [Abstract][Full Text] [Related]
16. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Kosmač M; Avčin T; Toplak N; Simonini G; Cimaz R; Curin Šerbec V Pediatr Res; 2011 Mar; 69(3):243-8. PubMed ID: 21131896 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy of inflammatory rheumatic diseases. Breedveld FC; van der Lubbe PA Br Med Bull; 1995 Apr; 51(2):493-502. PubMed ID: 7552078 [TBL] [Abstract][Full Text] [Related]
18. Improving the efficacy of antibody-based cancer therapies. Carter P Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803 [TBL] [Abstract][Full Text] [Related]
19. Biological therapies in rheumatic diseases. Conti F; Ceccarelli F; Massaro L; Cipriano E; Di Franco M; Alessandri C; Spinelli FR; Scrivo R Clin Ter; 2013; 164(5):e413-28. PubMed ID: 24217844 [TBL] [Abstract][Full Text] [Related]
20. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]